$IPSC

Carr Douglas sold $544 of IPSC

Carr Douglas (SVP Finance & Operations) sold 275 shares of Century Therapeutics, Inc. (IPSC) at $1.98 on 2026-08-03.

Original reporting
SEC EDGAR · Carr Douglas
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IPSC
Neutral
medium confidence
Mentioned
$IPSC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

An officer-level open-market sale was reported without a stated 10b5-1 plan; however, the dollar value is modest and does not include any company performance or guidance change.

02

Market read

Traders may briefly monitor for sentiment around insider selling, but the filing lacks new fundamental catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, which can increase interpretive sensitivity, but the article provides no additional context (e.g., tax, planned spending, or other concurrent transactions).

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

This is an SEC Form 4 insider transaction disclosure for Century Therapeutics, Inc. (IPSC).

Company-level read

Ticker impact

$IPSCNeutralMedium confidence
Context

Century Therapeutics (IPSC) disclosed an SVP Finance & Operations open-market sale of 275 shares at $1.9770 on 2026-08-03.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

Form 4 shows a direct open-market sale (code S) totaling about $543.68, with holdings after transaction at 504,819 shares. No new operational, regulatory, or financial guidance is provided.

Market effects

No sector-level implications; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is small relative to post-transaction holdings, it may reflect diversification or liquidity needs rather than negative expectations.

Key entities

  • Century Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Carr Douglas

    SVP Finance & Operations who sold 275 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IPSCHighAI 8/10

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

$IPSCMed

Century Therapeutics, Inc. (IPSC): Results of Operations and Financial Condition

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

$IPSCMedAI 8/10

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa